These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21763167)

  • 1. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.
    van der Beek NA; van Capelle CI; van der Velden-van Etten KI; Hop WC; van den Berg B; Reuser AJ; van Doorn PA; van der Ploeg AT; Stam H
    Mol Genet Metab; 2011; 104(1-2):129-36. PubMed ID: 21763167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease.
    Johnson EM; Roberts M; Mozaffar T; Young P; Quartel A; Berger KI
    Neuromuscul Disord; 2016 Feb; 26(2):136-45. PubMed ID: 26794303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
    Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
    Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness.
    Jones HN; Crisp KD; Moss T; Strollo K; Robey R; Sank J; Canfield M; Case LE; Mahler L; Kravitz RM; Kishnani PS
    J Pediatr Rehabil Med; 2014; 7(3):255-65. PubMed ID: 25260508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung MRI and impairment of diaphragmatic function in Pompe disease.
    Wens SC; Ciet P; Perez-Rovira A; Logie K; Salamon E; Wielopolski P; de Bruijne M; Kruijshaar ME; Tiddens HA; van Doorn PA; van der Ploeg AT
    BMC Pulm Med; 2015 May; 15():54. PubMed ID: 25943437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression from respiratory dysfunction to failure in late-onset Pompe disease.
    Berger KI; Chan Y; Rom WN; Oppenheimer BW; Goldring RM
    Neuromuscul Disord; 2016 Aug; 26(8):481-9. PubMed ID: 27297666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it useful to perform carbon monoxide diffusion capacity and respiratory muscle function tests in patients with multiple sclerosis without disability?
    Carvalho SR; Alvarenga Filho H; Papais-Alvarenga RM; Chacur FH; Dias RM
    Respirology; 2012 Jul; 17(5):869-75. PubMed ID: 22564062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease.
    Orlikowski D; Pellegrini N; Prigent H; Laforêt P; Carlier R; Carlier P; Eymard B; Lofaso F; Annane D
    Neuromuscul Disord; 2011 Jul; 21(7):477-82. PubMed ID: 21550241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.
    van Capelle CI; van der Beek NA; Hagemans ML; Arts WF; Hop WC; Lee P; Jaeken J; Frohn-Mulder IM; Merkus PJ; Corzo D; Puga AC; Reuser AJ; van der Ploeg AT
    Neuromuscul Disord; 2010 Dec; 20(12):775-82. PubMed ID: 20817528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
    Kuperus E; Kruijshaar ME; Wens SCA; de Vries JM; Favejee MM; van der Meijden JC; Rizopoulos D; Brusse E; van Doorn PA; van der Ploeg AT; van der Beek NAME
    Neurology; 2017 Dec; 89(23):2365-2373. PubMed ID: 29117951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study.
    van der Beek NA; de Vries JM; Hagemans ML; Hop WC; Kroos MA; Wokke JH; de Visser M; van Engelen BG; Kuks JB; van der Kooi AJ; Notermans NC; Faber KG; Verschuuren JJ; Reuser AJ; van der Ploeg AT; van Doorn PA
    Orphanet J Rare Dis; 2012 Nov; 7():88. PubMed ID: 23147228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
    Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
    Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.
    Van der Beek NA; Hagemans ML; Reuser AJ; Hop WC; Van der Ploeg AT; Van Doorn PA; Wokke JH
    Neuromuscul Disord; 2009 Feb; 19(2):113-7. PubMed ID: 19084399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular disorders.
    Fromageot C; Lofaso F; Annane D; Falaize L; Lejaille M; Clair B; Gajdos P; Raphaël JC
    Arch Phys Med Rehabil; 2001 Jan; 82(1):123-8. PubMed ID: 11239298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pompe disease: design, methodology, and early findings from the Pompe Registry.
    Byrne BJ; Kishnani PS; Case LE; Merlini L; Müller-Felber W; Prasad S; van der Ploeg A
    Mol Genet Metab; 2011 May; 103(1):1-11. PubMed ID: 21439876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.
    Müller-Felber W; Horvath R; Gempel K; Podskarbi T; Shin Y; Pongratz D; Walter MC; Baethmann M; Schlotter-Weigel B; Lochmüller H; Schoser B
    Neuromuscul Disord; 2007 Oct; 17(9-10):698-706. PubMed ID: 17643989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series.
    ElMallah MK; Desai AK; Nading EB; DeArmey S; Kravitz RM; Kishnani PS
    Pediatr Pulmonol; 2020 Mar; 55(3):674-681. PubMed ID: 31899940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy and fatigue in adults with Pompe disease.
    Güngör D; de Vries JM; Brusse E; Kruijshaar ME; Hop WC; Murawska M; van den Berg LE; Reuser AJ; van Doorn PA; Hagemans ML; Plug I; van der Ploeg AT
    Mol Genet Metab; 2013 Jun; 109(2):174-8. PubMed ID: 23603069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.